These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
458 related articles for article (PubMed ID: 37031435)
1. Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF Kang S; Lee MW; Song IC; Lee HJ; Yun HJ; Jo DY; Kim JS; Kwon JH; Kim JY; Lee KH; Ryu H J Cancer Res Clin Oncol; 2023 Aug; 149(10):7819-7829. PubMed ID: 37031435 [TBL] [Abstract][Full Text] [Related]
2. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476 [TBL] [Abstract][Full Text] [Related]
3. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. Ducreux M; Tabernero J; Grothey A; Arnold D; O'Dwyer PJ; Gilberg F; Abbas A; Thakur MD; Prizant H; Irahara N; Tahiri A; Schmoll HJ; Van Cutsem E; de Gramont A Eur J Cancer; 2023 May; 184():137-150. PubMed ID: 36921494 [TBL] [Abstract][Full Text] [Related]
4. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468 [TBL] [Abstract][Full Text] [Related]
5. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156 [TBL] [Abstract][Full Text] [Related]
6. Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer. Ten Hoorn S; Mol L; Sommeijer DW; Nijman L; van den Bosch T; de Back TR; Ylstra B; van Dijk E; van Noesel CJM; Reinten RJ; Nagtegaal ID; Koopman M; Punt CJA; Vermeulen L Clin Colorectal Cancer; 2023 Mar; 22(1):67-75. PubMed ID: 36564280 [TBL] [Abstract][Full Text] [Related]
7. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA; Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889 [TBL] [Abstract][Full Text] [Related]
8. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Maughan TS; Adams RA; Smith CG; Meade AM; Seymour MT; Wilson RH; Idziaszczyk S; Harris R; Fisher D; Kenny SL; Kay E; Mitchell JK; Madi A; Jasani B; James MD; Bridgewater J; Kennedy MJ; Claes B; Lambrechts D; Kaplan R; Cheadle JP; Lancet; 2011 Jun; 377(9783):2103-14. PubMed ID: 21641636 [TBL] [Abstract][Full Text] [Related]
9. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V; Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756 [TBL] [Abstract][Full Text] [Related]
10. Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen. Tanioka H; Shimada K; Tsuji A; Kochi M; Kim HM; Takahashi T; Denda T; Takagane A; Watanabe T; Kotaka M; Nakamura M; Sunakawa YU; Takeuchi M; Ichikawa W; Fujii M Anticancer Res; 2022 May; 42(5):2675-2681. PubMed ID: 35489740 [TBL] [Abstract][Full Text] [Related]
11. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335 [TBL] [Abstract][Full Text] [Related]
12. Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer. Chen B; Zheng D; Yu W; Huang C; Ye J; Han G; Zhuang J J Int Med Res; 2020 Sep; 48(9):300060520930440. PubMed ID: 32993393 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673 [TBL] [Abstract][Full Text] [Related]
14. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682 [TBL] [Abstract][Full Text] [Related]
15. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525 [TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China. Xu Y; Wang G; Zheng X; Chang W; Fu J; Zhang T; Lin Q; Lv Y; Zhu Z; Tang W; Xu J Eur J Surg Oncol; 2023 Nov; 49(11):106981. PubMed ID: 37455182 [TBL] [Abstract][Full Text] [Related]
17. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844 [TBL] [Abstract][Full Text] [Related]
18. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865 [TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study. Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945 [TBL] [Abstract][Full Text] [Related]
20. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]